TR201910511T4 - Hücre terapisi. - Google Patents

Hücre terapisi. Download PDF

Info

Publication number
TR201910511T4
TR201910511T4 TR2019/10511T TR201910511T TR201910511T4 TR 201910511 T4 TR201910511 T4 TR 201910511T4 TR 2019/10511 T TR2019/10511 T TR 2019/10511T TR 201910511 T TR201910511 T TR 201910511T TR 201910511 T4 TR201910511 T4 TR 201910511T4
Authority
TR
Turkey
Prior art keywords
dextran sulfate
reduce
cells
cell therapy
intraarterial
Prior art date
Application number
TR2019/10511T
Other languages
English (en)
Inventor
Korsgren Olle
Nilsson Bo
Original Assignee
Tx Medic Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tx Medic Ab filed Critical Tx Medic Ab
Publication of TR201910511T4 publication Critical patent/TR201910511T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/26—Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Dekstran sülfat, intravenöz olarak enjekte edilen hücrelerin pulmoner alımını azaltmak için kullanılır. Dekstran sülfat, intravenöz olarak enjekte edilen hücrelerin pulmoner alımını, intraarteriyal hücre enjeksiyonu kullanmanın bunlara eşlik eden riskleri ve yan etkileri olmaksızın hücrelerin intraarteriyal enjeksiyonu için elde edilen seviyelere indirgeyebilme kapasitesine sahiptir. Bu nedenle dekstran sülfat, bir denekte metastatik kanseri tedavi etmek için tümöre infiltre eden T-lenfositlerle birlikte bir bileşimde kullanılabilir.
TR2019/10511T 2010-07-16 2011-07-08 Hücre terapisi. TR201910511T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36499410P 2010-07-16 2010-07-16

Publications (1)

Publication Number Publication Date
TR201910511T4 true TR201910511T4 (tr) 2019-08-21

Family

ID=45469694

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/10511T TR201910511T4 (tr) 2010-07-16 2011-07-08 Hücre terapisi.

Country Status (8)

Country Link
US (1) US9446066B2 (tr)
EP (1) EP2593113B1 (tr)
DK (1) DK2593113T3 (tr)
ES (1) ES2732819T3 (tr)
HU (1) HUE044196T2 (tr)
PL (1) PL2593113T3 (tr)
TR (1) TR201910511T4 (tr)
WO (1) WO2012008908A1 (tr)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL88554A0 (en) * 1988-12-01 1989-07-31 Hadassah Med Org Compositions containing a compound binding to a heparin receptor
US5605938A (en) * 1991-05-31 1997-02-25 Gliatech, Inc. Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate
SE525461C3 (sv) 2002-11-28 2005-03-23 Prophymed Ab Ny användning av dextransulfat

Also Published As

Publication number Publication date
DK2593113T3 (da) 2019-07-08
EP2593113A1 (en) 2013-05-22
ES2732819T3 (es) 2019-11-26
PL2593113T3 (pl) 2019-09-30
EP2593113A4 (en) 2015-08-05
US9446066B2 (en) 2016-09-20
HUE044196T2 (hu) 2019-10-28
EP2593113B1 (en) 2019-04-24
US20130115200A1 (en) 2013-05-09
WO2012008908A1 (en) 2012-01-19

Similar Documents

Publication Publication Date Title
Chen et al. ROS: A “booster” for chronic inflammation and tumor metastasis
TR201809231T4 (tr) Hiyalüronidaz ve bir tümör-güdümlü taksan ile kombinasyon terapisi.
Marcelin et al. Privatization, financial development, property rights and growth
MX2015017485A (es) Uso de moleculas inhibidoras de semaforina-4d en combinacion con una terapia de modulacion inmune para inhibir crecimiento tumoral y metastasis.
EP4146216A4 (en) Triple combination therapy for enhancing cancer cell killing in cancers with low immunogenicity
TW201611843A (en) Methods of treatment with arginine deiminase
WO2009139921A3 (en) Microorganisms for preventing and treating neoplasms accompanying cellular therapy
MX342951B (es) Composiciones terapeuticamente activas y su metodo de uso.
MX351166B (es) Compuestos terapéuticamente activos y sus métodos de uso.
MX350432B (es) Compuestos terapeuticamente activos y sus metodos de empleo.
HK1220614A1 (zh) 耐化疗免疫细胞
MX2016004678A (es) Composiciones para el tratamiento del cancer.
TR201905909T4 (tr) Kanser tedavisi için anti-4-1bb antikorlarının ve adcc indükleyici antikorların kombinasyonları.
EP4523696A3 (en) Enhanced adoptive cell therapy
WO2011112953A3 (en) Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers
DK2252322T3 (da) Vaccinesammensætninger
EA201491584A1 (ru) Способы лечения немелкоклеточного рака легких c применением комбинированного лечения с ингибитором киназы tor
IL233543B (en) Methods for detecting 5t4-positive circulating tumor cells and methods of diagnosis of 5t4- positive cancer in a mammalian subject
EA201492160A1 (ru) Композиции, содержащие бензодиазепины короткого действия
NZ595641A (en) Humanized anti-egfl7 antibodies and methods using same
IN2015DN00143A (tr)
MX2014002990A (es) Tratamientos combinados que comprenden antagonistas de c-met y antagonistas de b-raf.
IN2014DN09228A (tr)
BR112013003579A2 (pt) adenovírus, células, e, métodos para tratar câncer
MX2011008994A (es) Metodos de usar sns - 595 para el tratamiento de sujetos con cancer con actividad reducida de brca2.